Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I clinical trial of HG030 in China for patients with NTRK/ ROS1 gene fusion-positive cancers.

Next Previous
X
Search
Trial Profile

Phase I clinical trial of HG030 in China for patients with NTRK/ ROS1 gene fusion-positive cancers.

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HG 030 (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors HitGen

    • Most Recent Events

    • 21 Nov 2020 New trial record
    • 30 Mar 2020 According to a HitGen media release, HG030 has obtained IND approval from the CDE (Center For Drug Evaluation), NMPA, Chinas Regulatory Authority for clinical trials and new products approval. The potential indications for HG030 are against the solid tumors harboring NTRK1/2/3/ROS1 fusion genes.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top